可乐定镇痛与中枢Ca2+的关系

用大鼠甩尾法和放射配基结合实验,探讨了可乐定镇痛与中枢Ca²⁺的关系。CaCl₂(1μmol/rat,icv)和EGTA(0.2μmol/rat,icv)分别拮抗和增强可乐定(1mg/kg,sc)的镇痛。戊脉安(0.1μmol/rat,icy)对可乐定(1 mg/kg,sc)镇痛无明显影响,但可部分翻转CaCl₂对可乐定镇痛的拮抗。CaCl₂(1×10^-3mol)对[³H]-可乐定结合无明显抑制。结果表明可乐定镇痛与脑室周围组织中Ca²⁺浓度变化密切相关,Ca²⁺至少部分需经对戊脉安敏感的钙通道进入细胞内方可拮抗可乐定镇痛。推沦:可乐定镇痛与神经元内Ca²⁺有关。     

四肽FMRFa对大鼠心室肌Na+/Ca2+交换的抑制

目的　研究四肽FMRFa对大鼠单个心室肌细胞Na⁺/Ca²⁺交换的作用。方法　用膜片钳全细胞记录法测定成年大鼠心室肌细胞Na⁺/Ca²⁺交换电流(I_Na⁺/Ca²⁺)和其他离子通道电流。结果　FMRFa对大鼠心室肌细胞I_Na⁺/Ca²⁺呈浓度依赖性抑制,100μmol·L^-1浓度时抑制内向和外向I_Na⁺/Ca²⁺密度分别达60.1%和56.5%,对内向电流及外向电流的IC₅₀分别为20μmol·L^-1和34μmol·L^-1。FMRFa5μmol·L^-1抑制I_Na⁺/Ca²⁺内向和外向电流密度分别为38.7%和34.9%,但FMRFa5μmol·L^-1及20μmol·L^-1对L型钙电流、钠电流、瞬时外向电流和内向整流钾电流均无显著抑制作用。结论　FMRFa对大鼠心室肌细胞是一个特异性Na⁺/Ca²⁺交换抑制剂。     

新的高强度高选择性阿片μ受体激动剂[11C]-羟甲芬太尼的合成

羟甲芬太尼(I)是一个新的高强度高选择性阿片μ受体激动剂。本文用cis-A-N-[1-(2-羟基-2-苯乙基)-3-甲基-4-哌啶基]-苯胺(II)或cis-N-[1-(苯甲酰甲基)-3-甲基-4-哌啶基]-苯胺(III)作为前体合成了[¹¹C]-羟甲芬太尼,以便用正电子发射断层扫描(PET)来观察μ受体。通过水解cis-A-羟甲芬太尼(I)和cis-N-[1-(苯甲酰甲基)-3-甲基-4-哌啶]-N-苯基丙酰胺(cis-IV)的4-N-丙酰基分别获得II和III。溴乙烷的格氏试剂与回旋加速器产生的[¹¹C]-二氧化碳反应后继而直接加入邻苯二甲酸二酰氯和2,6-二叔丁基吡啶生成同位素标记中间体[¹¹C]-丙酰氯。[¹¹C]-丙酰氯与OH-前体(II)反应后再经HPLC分离纯化直接得[¹¹C]-羟甲芬太尼;[¹¹C]-丙酰氯与酮-前体(III)反应后,再用硼氢化钠甲醇溶液处理,然后进行HPLC分离纯化得[¹¹C]-羟甲芬太尼。两种方法均可获得ll.1～14.8GBq/μmol的特异性放射化学纯[¹¹C]-羟甲芬太尼。总共耗时为40～50min(EOB)。     

葛根素和大豆甙元抑制[3H]氟硝西泮和体外大鼠脑膜的结合

从中药葛根中提取到两种苯二氮艹卓受体活性化合物:葛根素和大豆甙元。两种化合物在体外可抑制[3H]氟硝西泮和大鼠脑细胞膜的结合,IC₅₀值分别为18.46μmol·L^-1和15.43μmol·L^-1。大豆甙元还可抑制[³H]哌唑嗪和α1-肾上腺素受体的结合(IC₅₀值为89μmol·L^-1)。两种化合物的GABA比分别为1.11和1.12,提示两种黄酮化合物是苯二氮艹卓受体的拮抗剂或部分激动剂。Scatchardplot分析显示:两种化合物对[³H]氟硝西泮与膜结合的抑制作用是通过竞争性与非竞争性混合机制而实现的。     

从远志中分离鉴定出一种多巴胺受体活性化合物

从中药远志中提出一种多巴胺受体的配基,四氢非州防己胺。此化合物在体外可抑制[³H]SCH23390和[³H]螺哌隆与大鼠纹状体膜的结合,IC₅₀值分别为0.75±0.08μmol·L^-1和0.92±0.10μmol·L^-1。它在体外还能抑制[³H]哌唑嗪和大鼠脑皮质细胞膜结合(IC₅₀值为46μmol·L^-1),但不能改变[³H]QNB及[³H]muscimol对膜的结合。Scatchandplot分析显示此化合物对[³H]SCH23390和[³H]螺哌隆与膜结合的抑制作用是通过竞争性与非竞争性混合机制而实现的。     

乌骨藤中C21甾体苷诱导SACC-83和SACC-LM细胞凋亡的作用及其机制研究

目的 研究乌骨藤提取物C₂₁甾体苷对唾液腺腺样囊性癌（salivary adenoid cystic carcinomacv,SACC）低侵袭细胞株（salivary adenoid cystic carcinoma-83,SACC-83）和肺高转移细胞株（SACC-LM）增殖抑制和诱导凋亡的作用及其机制。方法 用不同浓度（5,10,20,40,60,80,100 μmol·L^-1） C₂₁甾体苷处理SACC-83和SACC-LM细胞48 h后,MTT法检测细胞活力,并计算药物的IC₂₀和IC₅₀;细胞克隆形成实验检测细胞增殖能力;流式细胞术检测SACC-83及SACC-LM细胞凋亡情况;实时荧光定量PCR和Western blot检测SACC-83和SACC-LM细胞Bcl-2、Bax、caspase 3的mRNA和蛋白的表达。结果 不同浓度的C₂₁甾体苷降低SACC-83和SACC-LM细胞活力,抑制细胞增殖,并且作用于SACC-83细胞C₂₁甾体苷的IC₂₀浓度为7.49 μmol·L^-1,IC₅₀浓度为38.34 μmol·L^-1;作用于SACC-LM细胞的C₂₁甾体苷IC₂₀浓度为9.30 μmol·L^-1,IC₅₀浓度为46.04 μmol·L^-1;细胞克隆集落形成明显减少。C₂₁甾体苷IC₂₀浓度分别促进SACC-83及SACC-LM细胞凋亡,且随着给药时间延长,凋亡率增加,具有显著性差异（P<0.05,P<0.01）。经7.49,9.30 μmol·L^-1 C₂₁甾体苷分别处理SACC-83及SACC-LM细胞后,Bcl-2的mRNA及蛋白水平显著降低（P<0.01）,而Bax、Caspase 3的mRNA和蛋白水平显著升高（P<0.05）。结论 乌骨藤C₂₁甾体苷抑制SACC-83及SACC-LM细胞增殖、促进凋亡,其作用机制可能与调控Bcl-2、Bax和Caspase 3表达有关。     

赛庚啶对离体犬心肌肌质网Ca2+,Mg2+—ATP酶活性和45Ca2+摄取功能的影响

当赛庚啶浓度在8×10^-6mol/L～2×10^-4mol/L之间时,该药对正常犬心肌肌质网Ca²⁺,Mg²⁺—ATP酶活性几乎没有影响,仅在10^-3mol/L时对该酶活性才有一定的抑制作用(抑制率为39.85%,P<0.01)。正常犬心肌肌质网的⁴⁵Ca²⁺摄取过程有明显的时间依赖性,至第30 min,其⁴⁵Ca²⁺摄取量可达312.79±22.25 nmol/mg protein.赛庚啶对心肌肌质网的~(45)Ca²⁺摄取有一定的抑制作用,其IC₅₀为1.94×10^-4mol/L。     

咖啡酸对雌、孕激素受体作用的探讨

本文采用放射受体结合法测定了咖啡酸及其主要代谢产物阿魏酸、间羟苯丙烯酸对家兔子宫胞浆孕酮受体的亲和力,IC₅₀分别为1.4,1.6和2.0mM。咖啡酸不影响假孕小鼠子宫对[³H]孕酮和[3H]雌二醇的摄取。提示咖啡酸抗早孕抑制孕激索作用并非由于竞争结合孕酮受体或减少甾体激素受体含量而致。     

大鼠肠道对左旋延胡索乙素及其消旋体的吸收差异研究

考察延胡索乙素(THP)的吸收机制，并研究其消旋体与左旋延胡索乙素(l-THP)在大鼠肠道的吸收差异。应用单向灌流模型，采用HPLC法测定THP及l-THP在灌流液中的浓度变化。灌流液中THP质量浓度为8，16，32 μg·mL^-1时，THP吸收速率常数和有效吸收系数均无统计差异(P>0.05)，各肠段的吸收速率常数和有效吸收系数也无统计差异(P>0.05)； l-THP和THP在大鼠肠道吸收存在显著性差异(P<0.05)； 在肠道灌流液中加入P-糖蛋白(P-gp)抑制剂维拉帕米后，THP吸收显著增加，而l-THP吸收几乎不变。THP在肠黏膜的转运为被动扩散过程，无特殊吸收窗口；THP消旋体与l-THP的吸收差异可能与P-gp与右旋THP的选择性结合有关。     

蝙蝠葛碱和粉防己碱对[3H]WEB 2086与体外牛脑前动脉平滑肌细胞结合的影响(英文)

用标记的血小板活化因子拮抗剂[³H]WEB 2086,在培养的牛脑前动脉平滑肌细胞上鉴定了血小板活化因子受体。结果表明在25℃时该细胞上存在两种与配基具有不同亲和力的受体结合位点,其中K_d-1=22.8±5.0 nmol·L^-1,K_d-2=186+20.5 nmol·L^-1;B_max-1=2.1±0.3 pmol/10⁴细胞,B_max-2=12.1±1-5 pmol/10⁶细胞。蝙蝠葛碱和粉防己碱均能抑制[³H]WEB2086与上述细胞的结合。     

Dopamine uptake inhibitors and releasing agents differentiated by the use of synaptosomes and field-stimulated brain slices in vitro.

Rat brain striatal synaptosomes or slices in vitro have been used to test the DA uptake inhibitory or releasing properties of certain drugs and to differentiate between these two processes.DA uptake into synaptosomes rapidly reaches saturation and the choice of incubation time is important for measuring inhibition. Thus nomifensine is apparently less active as an inhibitor when the incubation time is extended beyond the linear phase of uptake. As overall DA uptake reaches a plateau an extensive exchange of DA still occurs, presumably through a process of spontaneous release and reuptake. This phenomenon may provide an explanation for the apparent releasing properties of uptake inhibitors, the action of which would tend to favour the spontaneous release.Both nomifensine and amphetamine in high concentrations cause an increase in the amount of radioactivity in the medium when they are incubated with synaptosomes preloaded with [³H)DA. Their combined effects, however, are not additive, showing that different mechanisms must be involved. The difference is emphasised when the drugs are introduced under superfusion conditions where reuptake of DA is minimised. Amphetamine shows a very strong releasing effect, whereas nomifensine is inactive. Benztropine and methylphenidate both behave like nomifensine in these conditions.Similar results are found using preloaded, electrically-stimulated striatal slices, but in this case methylphenidate, as well as amphetamine, increases the overflow of radioactivity. With respect to newly-accumulated [³H]DA, nomifensine and benztropine can thus be considered as purely uptake inhibitors. The different releasing properties of methylphenidate and amphetamine may provide an explanation for their pharmacological differences.     

[3H]dopamine release by d-amphetamine from striatal synaptosomes of reserpinized rats

The injection of reserpine, 5 mg/kg i.p. (ipRes), the regimen employed by a majority of investigators, results in synaptosomal and vesicular preparations which are incompletely reserpinized as determined by [³H]dopamine ([³H]DA) accumulation. Reserpine administered by the subcutaneous route, 5 mg/kg (scRes), appears to produce complete reserpinization. Release of [³H]DA by d-amphetamine (Amph) was observed from striatal synaptosomes prepared both from normal rats and those pretreated with reserpine intraperitoneally but not from those injected subcutaneously. In the more completely reserpinized scRes synaptosomes, so little [³H]DA had accumulated that release by Amph was not measurable, indicating that if a labile, reserpine-resistant, extravesicular DA storage pool releasable by Amph is present under these conditions, it must be extremely small. In scRes monoamine oxidase (MAO)-inhibited preparations, Amph released preloaded [³H]DA located in the cytosol in the absence of functional vesicles. Although Chromatographic analysis of the superfusate from ipRes striatal synaptosomes showed that significant amounts of preloaded [³H]DA were released by Amph, the level of dihydroxyphenylacetic acid was not increased over controls, indicating that Amph releases only DA and not its metabolite and is also acting as a MAO inhibitor. No [³H]DA could be released by Amph from superfused hyposmotically shocked normal or ipRes synaptosomes, suggesting that an intact membrane is required for Amph-induced release.     

Artefactual inhibition of dopamine uptake by psychotropic drugs on striatal synaptosomal preparation

On striatal synaptosomal preparations, using a double labelling test, numerous antidepressant drugs demonstrated an inhibitory effect on [³H]DA uptake at the same high concentrations producing a [¹⁴C]DA release. This releasing effect was also shared by non-antidepressant agents and was observed on synaptosomes preloaded with [³H]5HT. The imipramine-induced release of DA was not modified by increasing concentration of K⁺, by decreasing concentration of Na⁺, by deleting Ca²⁺ from the incubation medium, or by blocking the catecholamine uptake systems with nomifensine or cocaine. The imipramine effect was reversible and was possibly initiated by a transient physico-chemical modification of the synaptosomal membrane. It was concluded that the DA uptake carrier is probably not involved in the effect of these drugs.     

Stimulation of synaptosomal tyrosine hydroxylation by phencyclidine in vitro

Phencyclidine (PCP), a potent psychoactive drug, produces some animal behavior that are belived to be mediated by dopaminergic and/or cholinergic neurons in the basal ganglia. In this study, we have monitored the effects of PCP in vitro on the synthesis, uptake, and release of dopamine (DA) in rat striatal synaptosomes. Using tyrosine hydroxylation as an index of DA synthesis, we observed a concentration-dependent stimulation of DA synthesis by PCP. The stimulatory effect was antagonized by reserpine (1 μM) and was observed only when synaptosomes were preincubated under conditions which prevented the spontaneous release of [³H]DA. Two hydroxylated metabolites of PCP were also tested and found to have little effect on tyrosine hydroxylation. Like PCP these metabolites are potent inhibitors of synaptosomal [³H]DA uptake, but they apparently lack PCP's ability to release synaptosomal DA. Taken together, these results support our hypothesis that PCP stimulates synaptosomal DA synthesis by releasing DA from an inhibitory pool.     

Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues

The effects of isomers and metabolites of amphetamine on the uptake of [³H]-catecholamines in synaptosomal preparations of the striatum and cortex of the rat were investigated. Dextroamphetamine was found to be four times more potent than the (?)-enantiomer against the uptake of [³H]-dopamine with striatal tissue. This difference may help to clarify the effects of the isomers on the development of stereotyped behaviour in the rat. The p-hydroxylation of amphetamine did not alter its potency, while β-hydroxylation of amphetamine or p-OH-amphetamine reduced the inhibitory potency markedly. With cerebral cortex, less than a 2-fold difference was found for the potencies of (+)- and (?)-amphetamine against the uptake of [³H]-norepinephrine. Although pretreatment with reserpine resulted in a marked inhibition of the initial uptake of norepinephrine, reserpine did not alter the relative potencies of the stereoisomers of amphetamine against the uptake of norepinephrine by cortex.     

Effects of mazindol on rat brain synaptosomal monoamine uptake

The effects of the anorectic drug mazindol on the uptake of [³H]NA and (³H]5HT by rat hypothalamic synaptosomes and the uptake of [³H]DA by rat striatal synaptosomes were investigated. In in vitro studies drugs were added to the incubation medium. In ex vivo experiments drugs were injected i.p. at various times prior to death and synaptosomal [³H] monoamine uptake subsequently determined. Two other anorectics (d-amphetamine and dl-fenfluramine) and two inhibitors of monoamine uptake (chlorimipramine and desipramine) were included for comparative purposes. Mazindol was a potent inhibitor of [³H]NA and [³H]DA uptake in vitro being approx. 0.5 times as potent as desipramine and d-amphetamine respectively. The abilities of mazindol, fenfluramine and desipramine to block the in vitro uptake of [³H]5HT were comparable and all three drugs were appreciably less potent than chlorimipramine. Following 1hr pretreatment, d-amphetamine was the most potent of the five drugs at inhibiting synaptosomal [³H]NA and [³H]DA uptake. Mazindol was approx. 2.5 times more potent than desipramine at blocking [³H]NA uptake. In contrast to the other drugs, pretreatment with large doses of mazindol had essentially no effect on hypothalamic synaptosomal [³H]5HT uptake. Results of ex vivo studies thus confirm in vivo findings that mazindol is a selective inhibitor of rat brain catecholamine uptake.     

Comparison of the release of [3h]dopamine from isolated corpus striatum by amphetamine,fenfluramine and unlabelled dopamine

Amphetamine-induced release of previously accumulated [³H]dopamine ([³H]DA) was compared to the release of [³H]]DA produced by unlabelled DA and fenfluramine. Like unlabelled DA, amphetamine was more potent than fenfluramine in releasing [³H]DA in all tissue preparations (untreated, pargyline-treated, and pargyline- and reserpine-treated corpus striatal slices). In tissue treated with both reserpine and pargyline, benztropine greatly reduced the efflux of [³H]DA produced by amphetamine and unlabelled DA but had only a slight effect on fenfluramine-induced release of [³H]DA. In the same tissue preparation, Q₁₀ values for the release of [³H]DA produced by 3 × 10^?7 M amphetamine (1.8) and 3 × l0^?6M unlabelled DA (1.7) were similar to that for the spontaneous release of [³H]DA (1.7). However, when the concentrations of amphetamine and unlabelled DA were increased to 10^?4 M, the Q₁₀ values for the release of [³H]DA were diminished at the lower temperatures. These results suggest that amphetamine may release [³H]DA by two mechanisms: (1) by accelerated exchange diffusion due to its use of the DA uptake carrier to enter into neurons (this would predominate at low concentrations of amphetamine), and (2) by passive entrance into neurons and displacement of [³H]Da from binding sites (this would predominate at high concentrations of amphetamine).     

EFFECTS OF RESERPINE ON THE CONTENT AND UPTAKE OF DOPAMINE AND NORADRENALINE IN RABBIT ARTERIES

1. Change with time of the content and uptake of dopamine (DA) and noradrenaline (NA) in the renal, superior mesenteric and femoral arteries and abdominal aorta of rabbit after reserpine administration was examined. Endogenous DA and NA were measured by high performance liquid chromatography coupled with electrochemical detector. 2. A single dose of reserpine (3 mg/kg, i.p.) maximally depleted the endogenous DA and NA contents in the four blood vessels 24 h after the administration; the ratios of reductions were 70–90% and approximately 90% of the normal levels, respectively. The DA contents in all four vessels recovered to the normal level within 4 days after reserpine. However, NA content did not recover to the normal levels within 30 days after reserpine except in the mesenteric artery. 3. The activity of dopamine β-hydroxylase (DBH) significantly increased in all four blood vessels 1 h after reserpine. Although the DBH activity returned to the normal level after 3 days in the mesenteric artery, it returned within 24 h in the other three vessels. 4. [³H]-Dopamine and [³H]-NA uptake were almost completely depressed 1 h after reserpine. The [³H]-NA uptake in four vessels recovered to the normal level 2–14 days after reserpine, and [³H]-DA uptake recovered after 30–45 days. Thus, the endogenous DA content in blood vessels was completely restored although DA uptake and NA content were still affected. 5. These results suggested that the recovery of stored DA after reserpine was faster than that of stored NA and the recovery of DA uptake after reserpine was slower than NA uptake. This indicates a possibility that a part of DA pool may be different from NA pool in adrenergic nerve terminals in the blood vessels.     

Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain

3,4-Methylenedioxymethamphetamine (MDMA) is a recently popularized recreational drug, although some have advocated its psychotherapeutic potential. Since the pharmacology of MDMA is largely uncharacterized, the stereochemical profiles of MDMA and some of its homologs were derived on inhibition of synaptosomal uptake of [3H]monoamines and compared to those of amphetamine and the hallucinogenic phenylisopropylamine 2,5-dimethoxy-4-methylamphetamine (DOM). In contrast to the 5-fold stereoselectivity observed with amphetamine, only the S-(+) enantiomer of MDMA and 3,4-methylenedioxyamphetamine (MDA) inhibited [3H]dopamine uptake into striatal synaptosomes. Neither stereoisomer of the alpha-ethyl homolog of MDMA, N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), inhibited [3H]dopamine uptake. The two stereoisomers of amphetamine and the MDMA-related compounds were equipotent in inhibiting [3H]norepinephrine uptake into hypothalamic synaptosomes. Both stereoisomers of MDMA, MDA and MBDB were potent inhibitors of [3H]serotonin uptake into hippocampal synaptosomes, but only S-(+)-amphetamine produced an appreciable inhibition of [3H]serotonin uptake. Neither stereoisomer of DOM inhibited synaptosomal uptake of any [3H]monoamine. These results suggest that MDMA and its homologs may be more closely related to amphetamine rather than to DOM in their biochemical mode of action. The pronounced effects of the methylenedioxy-substituted compounds on [3H]serotonin and [3H]norepinephrine uptake implicate these neurotransmitters in the pharmacological effects of these drugs.     

Striatal synaptosomal dopamine synthesis: evidence against direct regulation by an autoreceptor mechanism

Regulation of the rate-limiting step in dopamine (DA) synthesis was estimated in striatal synaptosomes by measuring the rate of hydroxylation of L-4-[3H]phenylalanine, a substrate of tyrosine hydroxylase (TH). DA inhibited hydroxylation with an IC50 of 0.2 microM. The concentration-response curve of DA-induced inhibition was not affected by the presence of 1 microM chlorpromazine, a phenothiazine DA antagonist. Sulpiride and haloperidol, DA antagonists of the benzamide and butyrophenone classes respectively, also failed to alter the inhibition of substrate hydroxylation by 1 microM DA, even at concentrations up to 10 microM. In contrast, a parallel 15 fold shift to the right in the concentration-response curve of DA-induced inhibition of hydroxylation was obtained when 10 microM nomifensine, a competitive DA uptake inhibitor, was added. Even in the presence of nomifensine, 1 microM chlorpromazine had no effect on the DA concentration-response curve. The addition of DMPH4, an artificial cofactor for TH, completely blocked DA-induced inhibition of enzymatic activity. These data suggest that direct autoreceptor control of synaptosomal TH activity does not exist in vitro, and that DA-induced inhibition of TH occurs subsequent to reuptake via classical feedback inhibition, presumably by competitive displacement of the necessary endogenous cofactor.